Megavog Tablet
Voglibose
0.3mg
Aristo Pharmaceuticals Ltd.
| Pack size | |
|---|---|
| Dispensing mode | |
| Source | |
| Agent | |
| Retail Price |
Indications
Megavog Tablet is used for:
Adult Dose
Oral
Diabetes mellitus
Adult: 200-300 mcg tid.
Elderly: Initiate at lower doses.
Child Dose
Renal Dose
Administration
Should be taken with food. Take just before meals.
Contra Indications
Inflammatory bowel disease; GI obstruction or patients predisposed to it; conditions which may deteriorate as a result of increased gas formation eg, hernia; severe ketosis; diabetic coma or pre-coma; severe infection; hypersensitivity; pregnancy; lactation. Not to be used as monotherapy in IDDM.
Precautions
History of laparotomy or ileus. Roemheld's syndrome, stenosis, severe hepatic or renal impairment. Child <18 yr; elderly. Monitor LFT. Treat hypoglycaemic episodes with glucose (not with sucrose).
Pregnancy-Lactation
Interactions
May enhance effects of other antidiabetics including insulin.
Adverse Effects
Side effects of Voglibose :
Flatulence; abdominal distension; diarrhoea; pain; skin reactions; hypoglycemia; increased LFT.
Potentially Fatal: Hepatotoxicity.
Mechanism of Action
Voligbose has general properties similar to acarbose and selectively inhibits α-glucosidase in the enteric canal, delaying the digestion and absorption of carbohydrate, thereby suppressing sharp increase in post-prandial plasma glucose.
Note
Megavog 0.3mg Tablet manufactured by Aristo Pharmaceuticals Ltd.. Its generic name is Voglibose. Megavog is availble in Nepal.
Farmaco Nepal drug index information on Megavog Tablet is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.